CA3081769C - Vaccin comprenant un polysaccharide de c. burnetii degraisse - Google Patents

Vaccin comprenant un polysaccharide de c. burnetii degraisse

Info

Publication number
CA3081769C
CA3081769C CA3081769A CA3081769A CA3081769C CA 3081769 C CA3081769 C CA 3081769C CA 3081769 A CA3081769 A CA 3081769A CA 3081769 A CA3081769 A CA 3081769A CA 3081769 C CA3081769 C CA 3081769C
Authority
CA
Canada
Prior art keywords
burnetii
vaccine
polysaccharide
delipidated
fever
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3081769A
Other languages
English (en)
Other versions
CA3081769A1 (fr
Inventor
Stephen Roger Graves
John Stenos
Moira Cecelia Graves
Rudolf Toman
Rodney Carbis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
OZQ Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OZQ Pty Ltd filed Critical OZQ Pty Ltd
Priority claimed from PCT/AU2018/051200 external-priority patent/WO2019084632A1/fr
Publication of CA3081769A1 publication Critical patent/CA3081769A1/fr
Application granted granted Critical
Publication of CA3081769C publication Critical patent/CA3081769C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des vaccins et des procédés d'utilisation de ceux-ci pour l'immunisation contre les infections par Coxiella burnetii et la fièvre Q. Le vaccin selon l'invention est destiné à la protection contre une infection par Coxiella burnetii, ou encore au traitement ou à la prévention d'au moins un symptôme de la fièvre Q. Le vaccin comprend un polysaccharide de C. burnetii délipidé dérivé d'un lipopolysaccharide de paroi cellulaire de C. burnetii. L'invention concerne également un vaccin conjugué destiné à la protection contre une infection par Coxiella burnetii, ou encore au traitement ou à la prévention d'au moins un symptôme de la fièvre Q, le vaccin comprenant un polysaccharide de C. burnetii délipidé dérivé d'un lipopolysaccharide de paroi cellulaire de C. burnetii lié à un support immunogène.
CA3081769A 2017-11-06 2018-11-06 Vaccin comprenant un polysaccharide de c. burnetii degraisse Active CA3081769C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904499 2017-11-06
AU2017904499A AU2017904499A0 (en) 2017-11-06 Vaccine
PCT/AU2018/051200 WO2019084632A1 (fr) 2017-11-06 2018-11-06 Vaccin

Publications (2)

Publication Number Publication Date
CA3081769A1 CA3081769A1 (fr) 2019-05-09
CA3081769C true CA3081769C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
EP0118831B1 (fr) Vaccins pour les bactéries gram-négatives et leur procédé de préparation
Robbins et al. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi
US9533032B2 (en) Protein matrix vaccines and related methods of making and administering such vaccines
EP0020356B1 (fr) Vaccins contre la pasteurellose
AU669854B2 (en) Escherichia coli O-polysaccharide-protein conjugate vaccine
EA006602B1 (ru) Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций
JP2007524621A (ja) ワクチン用担体タンパク質
KR20150076239A (ko) 새로운 점막 보조제 및 전달 시스템
US4693891A (en) Vaccine for Pseudomonas aeruginosa
JP2013504588A (ja) 免疫原性の高いタンパク質マトリックスワクチン
Jacques et al. Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate
Ghaderinia et al. Assessment of immunogenicity of alginate microparticle containing Brucella melitensis 16M oligo polysaccharide tetanus toxoid conjugate in mouse
NZ223841A (en) Iron-restriction proteins from pasteurella, vaccines and antibodies
Robbins et al. Haemophilus influenzae type b
US11045536B2 (en) Vaccine
CA3081769C (fr) Vaccin comprenant un polysaccharide de c. burnetii degraisse
Hamzavipour et al. Protection efficacy and immunogenicity of Clostridium chauvoei proteins as a subunit blackleg vaccine or an adjuvant for Clostridium perfringens epsilon toxoid
Abu-Baker et al. Synthesis, characterization, and immunological properties of LPS-based vaccines composed of O-polysaccharides conjugated with recombinant exoprotein a from Pseudomonas aeruginosa
EP0471954A2 (fr) Conjugué immunogénique d'oligosaccharides non toxiques dérivés du lipooligosaccharide de Bordetella pertussis
JP2023113631A (ja) クロストリジウム類毒素を含むワクチン
US20030068324A1 (en) Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
Kumar et al. Immunological studies on a modified multiple emulsion (w/o/w) bivalent Haemmorhagic septicemia vaccine incorporated with Pasteurella multocida P52 in the external aqueous phase
Carrasco Medina Investigation of a leukotoxin containing immune stimulating complex (ISCOM) vaccine and early immunization in dairy calves
Abu-baker et al. SYNTHESIS, CHARACTERIZATION, AND IMMUNOLOGICAL PROPERTIES OF LPS-BASED CONJUGATE VACCINE COMPOSED OF O-POLYSACCHARIDE AND RECOMBINANT EXOPROTEIN A FROM Pseudomonas aeruginosa.
Ryu Biological activities of fractions of type A Pasteurella multocida